Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Trading 02-04 11:12:51 EST

40.32

-0.38

-0.93%

High41.36	Low39.82	Vol197.23K
Open41.02	D1 Closing40.70	Amplitude3.78%
Mkt Cap4.24B	Tradable Cap3.50B	Total Shares105.19M
T/O7.94M	T/O Rate0.23%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":40.32,"timestamp":1770221567958,"preClose":40.7,"halted":0,"volume":197228,"delay":0,"changeRate":-0.0093366093366094,"floatShares":86875270,"shares":105188217,"eps":0.873455,"marketStatus":"Trading","change":-0.38,"latestTime":"02-04 11:12:51 EST","open":41.02,"high":41.36,"low":39.82,"amount":7941949.49208,"amplitude":0.037838,"askPrice":40.34,"askSize":75,"bidPrice":40.25,"bidSize":262,"shortable":3,"etf":0,"ttmEps":0.873455,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":40.7,"preHourTrading":{"tag":"盘前","latestPrice":40.99,"preClose":40.7,"latestTime":"09:27 EST","volume":364,"amount":14893.339552,"timestamp":1770215260045,"change":0.29,"changeRate":0.007125,"amplitude":0.009582},"postHourTrading":{"tag":"盘后","latestPrice":40.8,"preClose":40.7,"latestTime":"19:23 EST","volume":32840,"amount":1336615.9123,"timestamp":1770164629854,"change":0.1,"changeRate":0.002457,"amplitude":0.002457},"volumeRatio":0.29811,"impliedVol":0.854,"impliedVolPercentile":0.8008},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2607602919","title":"Corcept falls as FDA reveals it warned of CRL rejection for relacorilant","url":"https://stock-news.laohu8.com/highlight/detail?id=2607602919","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607602919?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:40","pubTimestamp":1769805626,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics (CORT) were slipping after the FDA updated a Complete Response Letter for the company’s relacorilant capsules, with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-falls-as-fda-reveals-it-warned-of-crl-rejection-for-relacorilant-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-falls-as-fda-reveals-it-warned-of-crl-rejection-for-relacorilant-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0390134368.USD","IE00BFMHRM44.USD","CORT","LU0566484027.USD","BK4585","BK4121","BK4588","CRL","LU1559883803.SGD","BK4007","LU0029874061.USD","LU0128526141.USD","BK4532","LU1815336091.USD","BK4530","LU0757428866.USD"],"gpt_icon":0},{"id":"2607704130","title":"Corcept Therapeutics Shares Down 16% After FDA Rejection Letter Reveals Repeated Warnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607704130?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:31","pubTimestamp":1769783482,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nFWN3YV0VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CORT","BK4007","LU1559883803.SGD","BK4532","LU0566484027.USD"],"gpt_icon":0},{"id":"2607049612","title":"BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607049612?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:12","pubTimestamp":1769782350,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX OncologyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: http","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL6N3YV0MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","VZ","HL","APD","TNXP","IE00B2Q91V27.USD","MENS","CDE","LU0683600562.USD","LU2404859667.USD","ALV","VEON","LU2404859741.USD","LU0498741890.SGD","LU0690374615.EUR","BK4146","AXP","SYK","BK4581","IE00BGHQF524.EUR","LU0266512473.USD","AU","RMD","LU0070217475.USD","LU0234572021.USD","DECK","KYIV","IE000M9KFDE8.USD","LU0690374961.EUR","BK4532","IE00BFXG1179.USD","BK4534","IE00BWXC8680.SGD","LU0170899867.USD","LXRX","PCVX","APA","ALXO","SNDR","BK4232","DVN","LU2347655156.SGD","LU1150488135.SGD","NEM","CORT","CVX","SG9999002521.SGD","LU0345780521.USD","XOM"],"gpt_icon":1},{"id":"2607045455","title":"BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2607045455","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607045455?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:30","pubTimestamp":1769779832,"startTime":"0","endTime":"0","summary":"BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings** Shares of drugmaker Corcept Therapeutics CORT.O fall 16.5% to $37.25 premarket** Last year, the U.S. FDA declined to approve Corcept's drug application for relacorilant to treat hypertension in Cushing's syndrome patients** FDA had warned Corcept \"on several occasions\" about concerns with the clinical program and to \"expect significant review issues\" if they submitted, the regulator's letter dated January 28 showed ** UBS analyst Ashwani Verma said the letter was made public on the FDA's website on Thursday around 4 pm E.T.** Corcept has one year to conduct new clinical trials or the application may be withdrawn, the letter stated** The original CRL was dated December 30, 2025, and this January 28 version is a corrected version issued in response to communications from Corcept, the letter showed** The company did not immediately respond to Reuters request for comment** CORT fell 30.9% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL4N3YV1AU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU1559883803.SGD","CORT","BK4532","BK4007"],"gpt_icon":0},{"id":"2606459112","title":"Top Growth Companies With High Insider Ownership In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606459112","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606459112?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:05","pubTimestamp":1769425550,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a period of volatility with major indexes posting consecutive weekly losses, investors are increasingly turning their attention to safe-haven assets like gold, which is nearing record highs. In such uncertain times, growth companies with high insider ownership can be particularly appealing, as they often demonstrate strong alignment between management and shareholder interests.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8043000-choice2-main-header/1585186922048","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8043000-choice2-main-header/1585186922048"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/retail/nyse-se/sea/news/top-growth-companies-with-high-insider-ownership-in-january-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/retail/nyse-se/sea/news/top-growth-companies-with-high-insider-ownership-in-january-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0516423091.SGD","BK4532","LU0516422440.USD","BK4085","BK4187","SPOT","LU2360106780.USD","LU1861215975.USD","BK4091","LU0441851309.USD","BK4096","LU0274383776.USD","BK4535","SG9999013486.USD","LU1935043536.SGD","LU0499858602.USD","LU1235294995.USD","SG9999002406.SGD","SG9999002604.SGD","SG9999002620.SGD","WDAY","LU2362541513.USD","BK4192","LU2065170008.USD","LU0082616367.USD","IE00BD6J9T35.USD","LU1861220033.SGD","BK4595","LU2152927971.USD","LU2360107168.USD","LU2362540622.SGD","LU2065171311.SGD","LU2065169927.USD","IE0009356076.USD","LU2125910500.SGD","LU2265009873.SGD","IE0031814969.USD","LU0786609619.USD","BK4220","IE0001KFT4U8.USD","SG9999005177.SGD","LU2125910849.SGD","LU1861217088.USD","IE0034224299.USD","BK4585","LU0264606111.USD","KRMN","SG9999002414.USD","LU0516422366.SGD","BK4555","BK4600","BK4007","LU2360107671.USD","BK4566","BK4551","IE00B5949003.HKD","SG9999002679.SGD","LU0289960550.SGD","LU0175139822.USD","BTDR","LU1559883803.SGD","SG9999013478.USD","LU0314104364.USD","PROP","BK4548","SES","LU0261945553.USD","LU2177674079.SGD","SG9999004360.SGD","LU1048588211.SGD","LU0251143029.SGD","LU2238330802.EUR","BK4558","LU0210637038.USD","SG9999014484.SGD","LU2065171402.SGD","LU0572939691.SGD","LU0737861269.HKD","BK4603","LU0719512351.SGD","LU0589944569.HKD","LU0499858438.USD","LU0572940350.SGD","LU1839390173.USD","CORT","BK4108","LU1046421795.USD","STUB","SE","LU0053671581.USD","BK4613","ALAB","BK4588","LU1804176565.USD","LU0348788117.USD","LU1989763005.USD","BK4503","LU2250418816.HKD","NIU","LU1303367103.USD","LU1242518931.SGD","LU0516423174.USD","LU2517655028.SGD","LU1691799644.USD","BK4571","LU2543165471.USD","LU2517655291.USD","LU0516422952.EUR","BK4141","LU0072462343.USD","LU1242518857.USD","LU0345775950.USD","LU0823038988.USD","BK4211","LU1989773731.SGD","SG9999006266.SGD","SG9999013460.SGD","LU2098885051.SGD","LU2290526834.HKD","BK4023","BK4170","LU0345776255.USD","IE0004445239.USD","LU2517655374.HKD","BK4543","LU0566484027.USD","SG9999014492.USD","LU2362541273.HKD","LU2008162690.USD","LU1983260115.SGD","LU0823039010.USD","LU1852331112.SGD","BK4528","LU0056508442.USD","GBFH","BK4213","SG9999001135.SGD","LU1823568750.SGD","LU2045819591.USD","LU1935042991.SGD","LU0048573645.USD","LU0979878070.USD","BK4581","LU1861220207.SGD","SGXZ58947870.SGD","LU2931357623.SGD","LU1770036033.HKD","BK4554","LU2089985449.USD","LU0532188223.SGD"],"gpt_icon":1},{"id":"2605409713","title":"Corcept Therapeutics put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605409713?lang=en_us&edition=fundamental","pubTime":"2026-01-23 23:15","pubTimestamp":1769181315,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Corcept Therapeutics (CORT) with 4,870 puts trading, or 4x expected. Most active are Feb-26 37.5 puts and Feb-26 40 calls, wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-put-volume-heavy-and-directionally-bearish-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-put-volume-heavy-and-directionally-bearish-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1559883803.SGD","BK4532","LU0566484027.USD","CORT","BK4007"],"gpt_icon":0},{"id":"2605408031","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Corcept Therapeutics (CORT), Intuitive Surgical (ISRG) and Vertex Pharmaceuticals (VRTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605408031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605408031?lang=en_us&edition=fundamental","pubTime":"2026-01-23 21:40","pubTimestamp":1769175614,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Corcept Therapeutics (CORT – Research Report), Intuitive Surgical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-corcept-therapeutics-cort-intuitive-surgical-isrg-and-vertex-pharmaceuticals-vrtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-corcept-therapeutics-cort-intuitive-surgical-isrg-and-vertex-pharmaceuticals-vrtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","LU0289739699.SGD","LU1989764664.SGD","LU1868836914.USD","IE0002141913.USD","LU2362541273.HKD","LU0029874061.USD","SG9999001176.USD","IE00BFXG0V08.USD","LU0114720955.EUR","LU0128526141.USD","VRTX","LU0238689110.USD","LU2433249047.HKD","SGXZ57979304.SGD","CORT","LU1093756325.SGD","LU2362541513.USD","LU1951198990.SGD","IE00BJT1NW94.SGD","LU1989764748.USD","ISRG","LU0058720904.USD","LU0354030438.USD","LU1868837300.USD","BK4532","LU1069344957.HKD","LU1093756168.USD","IE00B19Z9505.USD","LU0823434583.USD","VERX","LU1868837136.USD","LU2125909247.SGD","LU1057294990.SGD","BK4588","BK4082","LU0354030511.USD","LU1366192091.USD","LABU","IE00B19Z9P08.USD","LU0823434740.USD","LU2063271972.USD","LU1923623000.USD","LU1951200564.SGD","XLV","LU2023250504.SGD","HCSG","IE00BYQQ9H92.USD","BK4137"],"gpt_icon":0},{"id":"2605750304","title":"Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2605750304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605750304?lang=en_us&edition=fundamental","pubTime":"2026-01-23 17:54","pubTimestamp":1769162040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2026 04:54 ET (09:54 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"1186385322","title":"Corcept Therapeutics (CORT.US) Announces Positive Key Phase 3 Cancer Drug Results, Potential Launch Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1186385322","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186385322?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:52","pubTimestamp":1769125954,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT.US) announced that its pivotal Phase 3 clinical trial, ROSELLA, has met its primary endpoint of Overall Survival (OS). The trial evaluated the efficacy of its selective...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","LU0566484027.USD","CORT","BK4532"],"gpt_icon":0},{"id":"2605385411","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605385411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605385411?lang=en_us&edition=fundamental","pubTime":"2026-01-23 02:42","pubTimestamp":1769107366,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, IntelEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://ref","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL6N3YN0S2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADSK","GE","GGLL","PSQH","ABT","GGLS","TSLA","NEM","MULL","HBAN","SCCO","CRVS","TCBK","TDY","JANX","MKC","NEXT","INTC","LRCX","GLSI","VG","ORI","ELAN","MDCX","ACMR","KMI","RMBS","MUD","LTH","CTSH","ACI","JPM","CAL","PSKY","WYFI","NFE","BIOA","CORT","CRSH","PG","CBSH","WINA","DDOG","TSLR"],"gpt_icon":1},{"id":"2605419871","title":"Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2605419871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605419871?lang=en_us&edition=fundamental","pubTime":"2026-01-23 01:45","pubTimestamp":1769103916,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Corcept Therapeutics (CORT) to $105 from $90 and keeps a Buy ratin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-105-from-90-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-105-from-90-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2605418391","title":"Corcept Therapeutics rises 17.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605418391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605418391?lang=en_us&edition=fundamental","pubTime":"2026-01-22 23:06","pubTimestamp":1769094362,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) is up 17.7%, or $6.44 to $42.75. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-rises-17-7-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-rises-17-7-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT","LU0566484027.USD","LU1559883803.SGD","BK4007","BK4532"],"gpt_icon":0},{"id":"2605492696","title":"BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605492696?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:11","pubTimestamp":1769091106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Medicus Pharma, Lam Research, Applied DigitalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL6N3YN0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBAN","LU2129689605.HKD","MUD","PG","GE","GLSI","IE00B5MMRT66.SGD","LU0640476718.USD","LU0561508036.HKD","WYFI","89988","BIOA","MULL","LU0708995153.HKD","CORT","VG","BK1249","KMI","BMY","GB00BDT5M118.USD","JANX","ABT","LU2129689514.USD","LU0052750758.USD","LU0545039389.USD","CTSH","ALBmain","LU2152927971.USD","LU3063872942.SGD","LU2778985437.USD","APLD","ELAN","HBBD.SI","MDCX","CAL","BTBT","LU0315178854.USD","CRVS","LTH","LRCX","LU0231203729.USD","89888","LU0516423174.USD","RMBS"],"gpt_icon":1},{"id":"2605494562","title":"Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2605494562","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605494562?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:29","pubTimestamp":1769088553,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics ( ($CORT) ) has issued an update. On January 22, 2026, Corcept Therapeutics reported that its pivotal Phase 3 ROSELLA trial of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-phase-3-rosella-trial-achieves-survival-benefit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-phase-3-rosella-trial-achieves-survival-benefit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4007","CORT","BK4532"],"gpt_icon":0},{"id":"2605349175","title":"BUZZ-Corcept rises after ovarian cancer drug cuts risk of death in late-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2605349175","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605349175?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:28","pubTimestamp":1769088505,"startTime":"0","endTime":"0","summary":"BUZZ-Corcept rises after ovarian cancer drug cuts risk of death in late-stage trial** Shares of drugmaker Corcept Therapeutics CORT.O rise 19.5% to $43.39 premarket ** Co says its experimental cancer drug, relacorilant, met the main goal in a late-stage trial in patients with platinum-resistant ovarian cancer ** Says the drug with chemotherapy showed a 35% reduction in the risk of death ** CORT previously announced results from another late-stage trial in which the combination treatment helped delay progression of a type of ovarian cancer ** Relacorilant's marketing application is currently under review by the U.S. FDA with a target action date of July 11 ** CORT fell 30.9% in 2025 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4N3YN14Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","LU0566484027.USD","LU1559883803.SGD","BK4532"],"gpt_icon":0},{"id":"2605919364","title":"Corcept Therapeutics Shares up 34.82% Premarket After Experimental Ovarian Cancer Drug Meets Main Goal in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2605919364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605919364?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:21","pubTimestamp":1769088096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN18N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","BK4532","LU0566484027.USD","CORT","BK4007"],"gpt_icon":0},{"id":"2605919624","title":"Corcept Therapeutics reports ROSELLA trial meets primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2605919624","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605919624?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:10","pubTimestamp":1769087452,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) announced that ROSELLA, the company’s Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-reports-rosella-trial-meets-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-reports-rosella-trial-meets-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT","BK4007","LU1559883803.SGD","BK4532","LU0566484027.USD"],"gpt_icon":0},{"id":"2605994524","title":"Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605994524","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605994524?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:01","pubTimestamp":1769086895,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Incorporated announced that its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer met its primary endpoint of overall survival. The company previously reported that the trial also met its primary endpoint of improved progression-free survival, with patients receiving relacorilant plus nab-paclitaxel experiencing a 30 percent reduction in the risk of disease progression . Findings from the trial were first presented at ASCO 2025 and published simultaneously in The Lancet. Complete results from the ROSELLA trial will be presented at an upcoming medical conference. Corcept is in discussions with regulatory authorities in the U.S. and Europe regarding this treatment and is also studying relacorilant in other solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2Km0S0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","CORT","LU1559883803.SGD","LU0566484027.USD","BK4007"],"gpt_icon":0},{"id":"2605971499","title":"Corcept Therapeutics Inc - Phase 3 Rosella Trial Meets Overall Survival Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2605971499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605971499?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:00","pubTimestamp":1769086803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA6XVWHK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4532","CORT","BK4007"],"gpt_icon":0},{"id":"2605849997","title":"Corcept Therapeutics Inc - Data Show 35% Reduction in Risk of Death","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849997?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:00","pubTimestamp":1769086803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA6XVWHK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","LU1559883803.SGD","CORT","BK4532","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.1194},{"period":"1month","weight":0.0654},{"period":"3month","weight":-0.469},{"period":"6month","weight":-0.4306},{"period":"1year","weight":-0.3884},{"period":"ytd","weight":0.1695}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.454545,"avgChangeRate":0.014362},{"month":3,"riseRate":0.761905,"avgChangeRate":0.141286},{"month":4,"riseRate":0.52381,"avgChangeRate":-0.001402},{"month":5,"riseRate":0.5,"avgChangeRate":0.00703},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}